Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05462756 · ClinicalTrials.gov registry record · Phase 3
A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 730
- Enrollment target
NCT05462756 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 730 participants.
The verdict
NCT05462756, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 730 participants
- Enrollment target
Study Summary
The reason for this study is to evaluate if the once-weekly study drug insulin efsitora alfa (LY3209590) is safe and effective compared with daily insulin glargine in participants with Type 2 diabetes (T2D) that have already been treated with basal insulin and at least 2 injections per day of prandial insulin. The study consists of a 3-week screening/lead-in period, a 26-week treatment period and a 5-week safety follow-up period. The study will last up to 34 weeks.
Interventions
- DRUG Insulin Efsitora Alfa
- DRUG Insulin Lispro (U100)
- DRUG Insulin Glargine (U100)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 730 participants |
| Start Date | 2022-08-11 |
| Est. Completion | 2024-02-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05462756
The ClinicalTrials.gov registry entry for NCT05462756 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 730 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Insulin Efsitora Alfa is the first listed.
NCT05462756 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05462756 about?
NCT05462756 is a clinical study titled "A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections". The reason for this study is to evaluate if the once-weekly study drug insulin efsitora alfa (LY3209590) is safe and effective compared with daily insulin glargine in participants with Type 2 diabetes (T2D) that have already been treated with basal insulin and at least 2 injections per day of prandi...
What is the current status of trial NCT05462756?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 730 participants. The study started on 2022-08-11. Estimated completion is 2024-02-27.
What interventions are being tested in trial NCT05462756?
The interventions under investigation include: Insulin Efsitora Alfa (DRUG), Insulin Lispro (U100) (DRUG), Insulin Glargine (U100) (DRUG).
Who is sponsoring clinical trial NCT05462756?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.